PUBLIC COMPANY
save$BNTXBioNTech SE
$BNTX91.60-1.60%Mainz, DEupdated 9h ago
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
community read0 votes
🐶 often sniffed alongside
top 2pipeline
7
marketed
0
phase 3
3
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(7)
pipeline depth7 products
1Preclinical3Phase 23Phase 3
Phase 3
BNT-113
Recurrent Head And Neck Squamous Cell Carcinoma
Phase 3pumitamig
Non-Small Cell Lung Cancer
Phase 3trastuzumab pamirtecan
Endometrial Cancer
Phase 2BNT-111
Metastatic Melanoma
Phase 2DB-1311
Esophageal Squamous Cell Carcinoma (ESCC)
Phase 2sacituzumab drozuntecan
Epithelial Ovarian Cancer
PreclinicalUrinary Tract Infections Program
Urinary Tract Infections
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- phase1A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
- phase3A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
- phase2A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- phase1Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- phase3A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
- phase3A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- phase2A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 22, 26SELLPoetting Sierk· Chief Operating Officer−$5.53M↗
🐶 Hiring Signal
next earnings Nov 3, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that